HCW Biologics Stock (NASDAQ:HCWB)
Previous Close
$1.10
52W Range
$0.28 - $2.52
50D Avg
$0.51
200D Avg
$0.93
Market Cap
$35.83M
Avg Vol (3M)
$8.19M
Beta
0.84
Div Yield
-
HCWB Company Profile
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
HCWB Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CYT | Cyteir Therapeutics, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| IPSC | Century Therapeutics, Inc. |
| CSBR | Champions Oncology, Inc. |
| MNOV | MediciNova, Inc. |
| PHVS | Pharvaris N.V. |
| RZLT | Rezolute, Inc. |
| PEPG | PepGen Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| MOLN | Molecular Partners AG |
| PRDS | Pardes Biosciences, Inc. |
| STTK | Shattuck Labs, Inc. |
| ELYM | Eliem Therapeutics, Inc. |